Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in CP-CML Patients With Late Suboptimal Response to Imatinib
NCT01802450Phase 2Unknown
- Sponsor
- Fundación PETHEMA
- Start
- Mar 2013
- Primary completion
- Jun 2015
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in chronic myeloid leukemia (CML), sponsored by Fundación PETHEMA. Status: unknown.
02
Drugs
dasatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01802450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01802450.